Cutaneous manifestations of nontargeted and targeted chemotherapies

Semin Oncol. 2016 Jun;43(3):419-25. doi: 10.1053/j.seminoncol.2016.02.018. Epub 2016 Feb 23.

Abstract

Care of the oncologic patient requires an integral understanding of the adverse reactions of chemotherapy. With the advent of targeted agents and immunomodulating therapies, reactions to these newer treatments are of clinical interest. Cutaneous side effects of chemotherapeutic agents, including toxic erythema and mucositis, are common and may require cessation of treatment if associated with discomfort, superinfection, or negative impact on quality of life. This article reviews the cutaneous adverse reactions and treatment options of both conventional cytotoxic chemotherapeutic agents and newer targeted, multikinase inhibitors and immunomodulating therapies. An understanding of possible cutaneous reactions by all providers involved in the care of the oncologic patient is critical for prompt recognition, allowing for appropriate treatment and referral to dermatologists when necessary.

Keywords: Cutaneous adverse reactions; Cytotoxic chemotherapy; Immunotherapy; Multikinase inhibitors; Targeted chemotherapy; Toxic erythema.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • ErbB Receptors / antagonists & inhibitors
  • Erythema / chemically induced
  • Humans
  • Immunotherapy / adverse effects*
  • Immunotherapy / methods
  • MAP Kinase Kinase Kinases / antagonists & inhibitors
  • Molecular Targeted Therapy / adverse effects*
  • Molecular Targeted Therapy / methods
  • Mucositis / chemically induced
  • Nails / drug effects
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • EGFR protein, human
  • ErbB Receptors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • MAP Kinase Kinase Kinases